Viking Therapeutics posts third-quarter loss wider than analysts had expected
Viking Therapeutics reported a third-quarter net loss of $183.2 million against an IBES estimate of $126.7 million, per Reuters.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Viking Therapeutics reported a third-quarter net loss of $183.186 million, while the IBES consensus estimate was $126.7 million. Its operating loss came in at $187.112 million versus an expected $133.4 million. Operating expenses for the quarter also totaled $187.112 million, according to Reuters.
why it matters
For the broader market this is a routine result from a small biotech company. It matters mainly to shareholders and investors tracking spending on development, and the gap versus consensus may weigh on sentiment around the stock.
tags
instruments
sources
- BRIEF-Viking Therapeutics Q3 EPS USD -1.55 Vs. IBES Estimate USD -1.07 — Reuters, 28 October 2026 at 20:06 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗